

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 October 2024 (10.10.2024)



(10) International Publication Number
WO 2024/207047 A1

(51) International Patent Classification:

A61K 51/10 (2006.01) *A61P 35/00* (2006.01)
A61K 39/00 (2006.01) *A61P 35/04* (2006.01)
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/AU2023/050264

(22) International Filing Date:

04 April 2023 (04.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicants: **TELIX PHARMACEUTICALS (INNOVATIONS) PTY LTD** [AU/AU]; Level 4, 55 Flemington Road, North Melbourne, Victoria 3051 (AU). **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **WHEATCROFT, Michael Paul**; c/- Level 4, 55 Flemington Road, North Melbourne, Victoria 3051 (AU). **IVASHKEVICH, Alesia**; c/- Level 4, 55 Flemington Road, North Melbourne, Victoria 3051 (AU).

(74) Agent: **FPA PATENT ATTORNEYS PTY LTD**; Level 19, South Tower, 80 Collins Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF TREATING CANCERS EXPRESSING PDGFRALPHA

(57) Abstract: The invention relates to compositions comprising an olaratumab antibody conjugated to a therapeutic radioisotope, for treatment of cancers that express platelet derived growth factor receptor alpha (PDGFR-alpha), and methods of use thereof.

WO 2024/207047 A1